Abstract
Squamous cell carcinoma of the uterine cervix (CSCC) is one of the leading causes of death in Indian women. Protein tyrosine phosphatase receptor (PTPR) type J (also known as DEP1) is a recently reported tumour suppressor receptor phosphatase. Critical molecular analysis of PTPRJ/DEP1 (11p11.2) has not performed in CSCC to date. Here, we observed frequent downregulation of cancer samples (n=31) at the transcriptional level. Immunohistochemistry revealed concordant low expression of PTPRJ protein with a few samples showing intermediate expression. To probe for the cause of such downregulation of the gene in CSCC (n=155), we analysed the copy number and promoter methylation of PTPRJ. The genetic locus showed deletion (14.8%) and the promoter showed methylation (33.5%) of PTPRJ. To the best of our knowledge, for the first time we explored the molecular status of PTPRJ although we observed no statistically significant association with the prognosis of Indian CSCC patients (n=76). However, we observed enhanced expression of PTPRJ protein levels that contributes to effective cisplatin chemotherapy in the SiHa cell line. Thus, the present study paves the way for further research into the plausible mechanisms of downregulation of PTPRJ in cervical cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arbyn M., Weiderpass E., Bruni L., de Sanjose S., Saraiya M., Ferlay J. and Bray F. 2020 Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health 8, e191–e203.
Ardito F., Giuliani M., Perrone D., Troiano G. and Lo Muzio L. 2017 The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int. J. Mol. Med. 40, 271–280.
Balavenkatraman K. K., Jandt E., Friedrich K., Kautenburger T., Pool-Zobel B. L., Ostman A. and Bohmer F. D. 2006 DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. Oncogene 25, 6319–6324.
Bollu L. R., Mazumdar A., Savage M. I. and Brown P. H. 2017 Molecular pathways: targeting protein tyrosine phosphatases in cancer. Clin. Cancer Res. 23, 2136–2142.
Bononi A., Agnoletto C., Marchi E. D., Marchi S., Patergnani S., Bonora M. et al. 2011 Protein kinases and phosphatases in the control of cell fate. Enzyme Res. 2011, 329098.
Casagrande S., Ruf M., Rechsteiner M., Morra L., Brun-Schmid S., Teichman A. et al. 2013 The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. J. Pathol. 229, 525–534.
Chakraborty C., Mitra S., Roychowdhury A., Samadder S., Dutta S., Roy A. et al. 2018 Deregulation of LIMD1-VHL-HIF-1alpha-VEGF pathway is associated with different stages of cervical cancer. Biochem. J. 475, 1793–1806.
Chandrashekar D. S., Bashel B., Balasubramanya S. A. H., Creighton C. J., Ponce-Rodriguez I., Chakravarthi B. and Varambally S. 2017 UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649–658.
He R. J., Yu Z. H., Zhang R. Y. and Zhang Z. Y. 2014 Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol. Sinica 35, 1227–1246.
Iuliano R., Pera I. L., Cristofaro C., Baudi F., Arturi F., Pallante P. et al. 2004 The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 23, 8432–8438.
Iuliano R., Palmieri D., He H., Iervolino A., Borbone E., Pallante P. et al. 2010 Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr.-Relat. Cancer 17, 1001–1006.
Jeon M. and Zinn K. 2009 Receptor tyrosine phosphatases control tracheal tube geometries through negative regulation of EGFRsignaling. Development 136, 3121–3129.
Koraneekit A., Limpaiboon T., Sangka A., Boonsiri P., Daduang S. and Daduang J. 2018 Synergistic effects of cisplatin-caffeic acid induces apoptosis in human cervical cancer cells via the mitochondrial pathways. Oncol. Lett. 15, 7397–7402.
Livak K. J. and Schmittgen T. D. 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 25, 402–408.
Loginov V. I., Maliukova A. V., Seregin lu A., Khodyrev D. S., Kazubskaia T. P., Ermilova V. D. et al. 2004 Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors. Mol. Biol. 38, 654–667.
Maiti G. P., Mondal P., Mukherjee N., Ghosh A., Ghosh S., Dey S. et al. 2013 Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One 8, e63440.
Moarii M., Boeva V., Vert J. P. and Reyal F. 2015 Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics 16, 873.
Narayan G. and Murty V. V. 2010 Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol. 6, 1643–1652.
Omerovic J., Clague M. J. and Prior I. A. 2010 Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/AKT activation in Ras-mutated cancer cells. Biochem. J. 426, 65–72.
Perrone F., Suardi S., Pastore E., Casieri P., Orsenigo M., Caramuta S. et al. 2006 Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 12, 6643–6651.
Rhodes D. R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D. et al. 2004 ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1–6.
Roychowdhury A., Samadder S., Das P., Mandloi S., Addya S., Chakraborty C. et al. 2017a Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. Biochim. Biophys. Acta Gen. Subj. 1861, 2899–2911.
Roychowdhury A., Samadder S., Islam S., Chaudhury K., Roy A., Banerjee D. et al. 2017b Identification of changes in the human papilloma virus 16 (HPV16) genome during early dissemination of cervical cancer cells may complement histological diagnosis of lymph node metastasis. Pathol. Oncol. Res. 23, 845–852.
Roychowdhury A., Samadder S., Mazumder D. I., Das P., Basu M., Mondal R. et al. 2019 IGF2 is deregulated during the Development of Uterine Cervical Carcinoma in Indian Patients. Biochem. Genet. 57, 638–651.
Roychowdhury A., Samadder S., Das P., Mazumder D. I., Chatterjee A., Addya S. et al. 2020 Deregulation of H19 is associated with cervical carcinoma. Genomics 112, 961–970.
Ruivenkamp C. A., Wezel T., Zanon C., Stassen A. P. M., Vlcek C., Csikós T. et al. 2002 PTPRJ is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. 31, 295–300.
Spring K., Fournier P., Lapointe L., Chabot C., Roussy J., Pommey S. et al. 2015 The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.Oncogene 34, 5536–5547.
Takahashi T., Takahashi K., Mernaugh R. L., Tsuboi N., Liu H. and Daniel T. O. 2006 A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis Blood 108, 1234–1242.
Tarcic G., Boguslavsky S. K., Wakim J., Kiuchi T., Liu A., Reinitz F. et al. 2009 An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis Curr. Biol. 19, 1788–1798.
Tonks N. K. 2013 Protein tyrosine phosphatases–from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280, 346–378.
Yan C. M., Zhao Y. L., Cai H. Y., Miao G. Y. and Ma W. 2015 Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A. Oncol. Rep. 33, 1737–1744.
Yao Z., Darowski K., St-Denis N., Wong V., Offensperger F., Villedieu A. et al. 2017 A global analysis of the receptor tyrosine kinase-protein phosphatase interactome. Mol. Cell 65, 347–360.
Acknowledgements
The authors thank the Director, Chittaranjan National Cancer Institute, Kolkata, India. This work was supported by University Grants Commission (UGC)-NET Fellowship grant (Sr. No. 2061430780, Ref No.: 22/06/2014(i)EU-V) to Ms M. Basu DST-INSPIRE Fellowship grant sanction order: No. IF170005/2017, (ii) EO-V dated 17.07.2017) to Mrs P. Dutta, UGC-JRF/NET grant [Sr. No. 2121130723] to Mr S. Samadder from University Grants Commission (UGC), and grant from the Council of Scientific & Industrial Research (CSIR), Government of India (No. 60(0111)/14/EMR-II of dt 03/11/2014) to Dr C. K. Panda. NASI Senior Scientist Platinum Jubilee Fellowship (2020) awarded to Dr C. K. Panda. NASI Senior Scientist Platinum Jubilee Fellowship (2020) of Dr. C. K. Panda of dt. 30.12.2019.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: Durgadas P. Kasbekar
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Roychowdhury, A., Basu, M., Pal, D. et al. PTPRJ is downregulated in cervical squamous cell carcinoma. J Genet 101, 29 (2022). https://doi.org/10.1007/s12041-022-01368-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12041-022-01368-9